News, reviews and podcasts from annual scientific meetings and symposiums around the world.
WCLC 2024: NeoCOAST-2 Data shows combination of durvalumab with novel agents increases pathological responses in resectable NSCLC
Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd…